Soo K C, Ward M, Roberts K R, Keeling F, Carter R L, McCready V R, Ott R J, Powell E, Ozanne B, Westwood J H
Head Neck Surg. 1987 Jul-Aug;9(6):349-52. doi: 10.1002/hed.2890090608.
A pilot study was carried out to assess the value of a radiolabeled antibody against epidermal growth factor receptor (EGFR1) in localizing tumors in patients with squamous carcinomas of the head and neck. Positive images of large tumours (greater than 3 cm diameter) were obtained in 8 of 11 patients after intravenous administration of 111indium-labeled EGFR1. Two patients gave equivocal results, while negative scans were obtained from the patient with the smallest tumor (1 cm diameter). There were no false-positive images. The success of this study in localizing relatively large squamous carcinomas indicates that the antibody should be evaluated in patients with smaller tumors to establish the limits of detection of the technique.
开展了一项初步研究，以评估一种针对表皮生长因子受体（EGFR1）的放射性标记抗体在对头颈部鳞状细胞癌患者进行肿瘤定位中的价值。11名患者静脉注射111铟标记的EGFR1后，11名患者中有8名获得了大肿瘤（直径大于3厘米）的阳性图像。两名患者结果不明确，而肿瘤最小（直径1厘米）的患者扫描结果为阴性。没有假阳性图像。这项在定位相对较大鳞状细胞癌方面的研究取得成功，表明应在肿瘤较小的患者中评估该抗体，以确定该技术的检测限度。
